CD8A and neoplasm: Our findings suggest that candidates for anti-PD-1/PD-L1 therapy extend beyond POLEm and MMRd ECs, and assessment of additional markers such as tumor differentiation, level of CD3+ and CD8+ TILs, and expression of PD-1 and PD-L1 may be helpful for patient selection.